The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement

No abstract is available for this paper.

• Publication year

  2010

• Venue

  European Respiratory Journal

• Publication date

  2010-06-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1183/09031936.00028510PMID 20530046
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease

  2012cited by this paper
• Certolizumab pegol for the treatment of Crohn’s disease

  2011cited by this paper
• Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register

  2010cited by this paper
• Tuberculosis contact investigation in low prevalence countries: a European consensus

  2010cited by this paper
• Risk factors for idiopathic orbital inflammation: a case–control study

  2010cited by this paper
• Infliximab, azathioprine, or combination therapy for Crohn's disease.

  2010cited by this paper
• Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis

  2009cited by this paper
• Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

  2009cited by this paper
• Long‐term maintenance treatment of moderate‐to‐severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort

  2009cited by this paper
• Usefulness of interferon-gamma release assays for diagnosing TB infection and problems with these assays

  2009cited by this paper
• Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada.

  2009cited by this paper
• Use of the T-SPOT.TB Assay to Detect Latent Tuberculosis Infection Among Rheumatic Disease Patients on Immunosuppressive Therapy

  2009cited by this paper
• The Likelihood of an Indeterminate Test Result from a Whole-Blood Interferon-&ggr; Release Assay for the Diagnosis of Mycobacterium tuberculosis Infection in Children Correlates With Age and Immune Status

  2009cited by this paper
• TNF-alpha blockers in inflammatory bowel diseases: practical consensus recommendations and a user's guide.

  2009cited by this paper
• LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement

  2009cited by this paper
• Clinical Remission in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Anti-Tumor Necrosis Factor Agents

  2009cited by this paper
• Screening of tuberculosis by interferon-gamma assay before biologic therapy for rheumatoid arthritis.

  2009cited by this paper
• Performance of tests for latent tuberculosis in different groups of immunocompromised patients.

  2009cited by this paper
• The spectrum of latent tuberculosis: rethinking the biology and intervention strategies

  2009cited by this paper
• Etanercept Treatment for Children and Adolescents with Plaque Psoriasis

  2009cited by this paper
• Empfehlungen für das Tuberkulose-Screening vor Gabe von TNF-α-Inhibitoren bei rheumatischen Erkrankungen

  2009cited by this paper
• Comparison of Screening Procedures for Mycobacterium tuberculosis Infection Among Patients with Inflammatory Diseases

  2009cited by this paper
• British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009

  2009cited by this paper
• The treatment of lupus pernio: results of 116 treatment courses in 54 patients.

  2009cited by this paper
• QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases

  2009cited by this paper
• Novel screening tools for latent tuberculosis: time to leave an old friend?

  2009cited by this paper
• An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa

  2009cited by this paper
• Infectious complications of tumor necrosis factor blockade

  2009cited by this paper
• Juvenile folliculotropic and ichthyosiform mycosis fungoides

  2009cited by this paper
• Antinuclear antibodies associate with loss of response to antitumour necrosis factor‐α therapy in psoriasis: a retrospective, observational study

  2009cited by this paper
• Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals.

  2009cited by this paper
• Long‐term outcome of maintenance infliximab therapy in children with Crohn's disease

  2009cited by this paper
• Interferon-γ release assays do not identify more children with active tuberculosis than the tuberculin skin test

  2009cited by this paper
• Adalimumab treatment for severe recalcitrant chronic plaque psoriasis

  2009cited by this paper
• Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

  2009cited by this paper
• Agreement Between Quantiferon-TB Gold Test and Tuberculin Skin Test in the Identification of Latent Tuberculosis Infection in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis

  2009cited by this paper
• Dominant-negative tumor necrosis factor protects from Mycobacterium bovis Bacillus Calmette Guérin (BCG) and endotoxin-induced liver injury without compromising host immunity to BCG and Mycobacterium tuberculosis.

  2009cited by this paper
• Comparison of interferon γ release assays and conventional screening tests before tumour necrosis factor α blockade in patients with inflammatory arthritis

  2009cited by this paper
• Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon‐γ release assay vs. tuberculin skin test

  2009cited by this paper
• Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans.

  2009cited by this paper
• Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry

  2008cited by this paper
• Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network.

  2008cited by this paper
• Long-Term Management of Generalized Pustular Psoriasis with Infliximab: Case Series

  2008cited by this paper
• Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register

  2008cited by this paper
• Tumour necrosis factor antagonists: structure, function, and tuberculosis risks.

  2008cited by this paper
• Tumor Necrosis Factor-α Inhibitor-Induced Psoriasis or Psoriasiform Exanthemata

  2008cited by this paper
• Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year.

  2008cited by this paper
• Paediatric tuberculosis.

  2008cited by this paper
• Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

  2008cited by this paper
• Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept.

  2008cited by this paper
• Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis.

  2008cited by this paper
• Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population.

  2008cited by this paper
• Meta-analysis: New Tests for the Diagnosis of Latent Tuberculosis Infection: Areas of Uncertainty and Recommendations for ResearchMenzies D, Pai M, Comstock G (McGill Univ, Montreal; Johns Hopkins Univ, Baltimore, Md) Ann Intern Med 146:340–354, 2007§

  2008cited by this paper
• Comparison of Treatment Strategies in Early Rheumatoid Arthritis: A Randomized Trial

  2008cited by this paper
• Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

  2008cited by this paper
• Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee.

  2008cited by this paper
• Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis

  2008cited by this paper
• Etanercept treatment for children and adolescents with plaque psoriasis.

  2008cited by this paper
• Performance of two commercial blood IFN-γ release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-α treatment

  2008cited by this paper
• Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

  2008cited by this paper
• Systematic Review: T-Cellbased Assays for the Diagnosis of Latent Tuberculosis Infection: An Update

  2008cited by this paper
• Update on biologics in juvenile idiopathic arthritis

  2008cited by this paper
• Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis.

  2008cited by this paper
• Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register

  2008cited by this paper
• Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment.

  2008cited by this paper
• Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action.

  2008cited by this paper
• American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

  2008cited by this paper
• Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.

  2008cited by this paper
• Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.

  2007cited by this paper
• Differences in Reactivation of Tuberculosis Induced from Anti-TNF Treatments Are Based on Bioavailability in Granulomatous Tissue

  2007cited by this paper
• Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.

  2007cited by this paper
• T cell-based diagnosis of childhood tuberculosis infection

  2007cited by this paper
• Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy.

  2007cited by this paper
• Focus on adverse events of tumour necrosis factor α blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients

  2007cited by this paper
• Brief Communication: Characteristics of Spontaneous Cases of Tuberculosis Associated with Infliximab

  2007cited by this paper
• The new IGRA and the old TST: making good use of disagreement.

  2007cited by this paper
• A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

  2007cited by this paper
• Certolizumab pegol for the treatment of Crohn's disease.

  2007cited by this paper
• Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

  2007cited by this paper
• Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.

  2007cited by this paper
• Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)‐infected individuals enrolled with suspected active tuberculosis: a pilot study

  2007cited by this paper
• Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers.

  2007cited by this paper
• Antirheumatic drugs and the risk of tuberculosis.

  2007cited by this paper
• Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis.

  2007cited by this paper
• Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti‐tumor necrosis factor &agr; agents

  2007cited by this paper
• Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

  2007cited by this paper
• A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.

  2007cited by this paper
• Potential effect of NICE tuberculosis guidelines on paediatric tuberculosis screening

  2007cited by this paper
• Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy

  2007cited by this paper
• Persistent clinical efficacy and safety of anti-tumour necrosis factor α therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response

  2007cited by this paper
• The Role of Anti-Tumor Necrosis Factor-α Therapy in Pyoderma Gangrenosum Associated with Inflammatory Bowel Disease

  2007cited by this paper
• In vitro observations of T cell responsiveness to recall antigens during tumor necrosis factor-alpha-blocking therapy in patients with ankylosing spondylitis.

  2007cited by this paper
• An open‐label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa

  2007cited by this paper
• Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.

  2007cited by this paper
• Tumor necrosis factor and tuberculosis.

  2007cited by this paper
• A Virus-Like Particle-Based Vaccine Selectively Targeting Soluble TNF-α Protects from Arthritis without Inducing Reactivation of Latent Tuberculosis

  2007cited by this paper
• Maintenance therapy with certolizumab pegol for Crohn's disease.

  2007cited by this paper
• Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon γ assay

  2007cited by this paper
• Comparison of Treatment Strategies in Early Rheumatoid Arthritis

  2007cited by this paper
• Erratum: Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-α blockers: The GISEA study (Journal of Rheumatology (2007) 34, (1670-1673))

  2007cited by this paper

• Screening for Tuberculosis Infection in Rheumatology Practice: An Update

  2026cites this paper
• Host- and pathogen-related determinants of pulmonary versus extrapulmonary tuberculosis

  2026cites this paper
• Minimizing missed latent tuberculosis infection under adalimumab: real-world data from a BCG-vaccinated cohort

  2026cites this paper
• Peritoneal tuberculosis mimicking malignancy on FDG PET/CT in a patient with ankylosing spondylitis on adalimumab: a diagnostic challenge

  2026cites this paper
• Disseminated Tuberculosis Driving Secondary Haemophagocytic Lymphohistiocytosis Following Adalimumab and Treatment for Latent Tuberculosis.

  2025cites this paper
• Tuberculosis Trends in the Post‐COVID‐19 Era: Is It Going to be a Global Concern?

  2025cites this paper
• II. Diagnostic Approach for Inflammatory Bowel Disease

  2025cites this paper
• Mycobacterium tuberculosis Infects Human Visceral White Adipocytes and Expresses Dormancy Genes and Inflammatory Cytokines: The Role of Visceral Adipocytes in Latent Tuberculosis Infection

  2025cites this paper
• In vitro and in vivo efficacy of PI3Kγ inhibitor AS605240 in controlling mycobacterial infections.

  2025cites this paper
• Latent tuberculosis infection screening in patients with inflammatory bowel disease: a nationwide retrospective cohort study in South Korea comparing IGRA alone versus a combination of TST and IGRA

  2025cites this paper
• A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX

  2025cites this paper
• Functional and phenotypic characterization of peripheral blood mononuclear cells from tuberculosis patients in Southern Thailand

  2025cites this paper
• Tuberculosis incidence in patients treated with secukinumab – a real-world study in Brazil

  2025cites this paper
• Thalidomide as an Adjunctive Therapy for HIV-Tuberculosis–Associated Immune Reconstitution Inflammatory Syndrome: A Case Series

  2025cites this paper
• Evaluating Secukinumab as Treatment for Axial Spondyloarthritis and Psoriatic Arthritis in Patients with Comorbidities: Multicenter Real-Life Experience

  2025cites this paper
• Concurrent Psoriatic Arthritis and Ankylosing Spondylitis in a Middle-Aged Man: A Case Report With Peripheral Joint Functional and Quality of Life Assessment

  2025cites this paper
• Retrospective evaluation of active tuberculosis cases in terms of chemoprophylaxis indication: A cross-sectional study

  2025influential citation
• Model systems to study Mycobacterium tuberculosis infections: an overview of scientific potential and impediments

  2025cites this paper
• Prevention of Tuberculosis in Patients Treated With Biological Therapies: Twenty Years' Experience in a Specialised Tuberculosis Clinic in a Low-prevalence Country.

  2025cites this paper
• Clinical Perspective of Multiple Drug Resistance Tuberculosis: An Overview.

  2025cites this paper
• Incidence rates of tuberculosis and inflammatory bowel disease in patients with ankylosing spondylitis treated with biologics in Korea

  2025cites this paper
• Latent and Manifest Tuberculosis in Patients with Rheumatoid Arthritis Treated with Anticytokine Therapy

  2025cites this paper
• Pulmonary Complications in Connective Tissue Disease‐Associated Interstitial Lung Disease

  2025cites this paper
• Advancements in therapeutic strategies and drug development for inflammatory bowel diseases

  2025cites this paper
• Host-Mediated Antimicrobial Effects and NLRP3 Inflammasome Modulation by Caulerpin and Its Derivatives in Macrophage Models of Mycobacterial Infections

  2025cites this paper
• Tuberculosis infection in rheumatological patients receiving tumor necrosis factor – alpha inhibitors

  2025cites this paper
• Risk Factors of Progression to Active Tuberculosis in Rheumatic Patients With Latent Tuberculosis: A Retrospective Study

  2025cites this paper
• Interleukin-17A Inhibitors in Patients with Psoriasis and Tuberculosis Infection: A 2-Year Prospective Study on Safety Without Preventive Treatment

  2024influential citation
• The Known and Unknown “Knowns” of Human Susceptibility to Coccidioidomycosis

  2024cites this paper
• Reduced gut microbiota diversity in ulcerative colitis patients with latent tuberculosis infection during vedolizumab therapy: insights on prophylactic anti-tuberculosis effects

  2024cites this paper
• The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy.

  2024cites this paper
• Dysregulation of T cell response in the pathogenesis of inflammatory bowel disease

  2024cites this paper
• The Dilemma of Balancing Anti-Tumor Necrosis Factor-Alpha (Anti-TNF-α) Biologics for Psoriatic Arthritis Control With the Risk of Severe Systemic Infection

  2024cites this paper
• Understanding the development of tuberculous granulomas: insights into host protection and pathogenesis, a review in humans and animals

  2024cites this paper
• Real-life data of etanercept efficacy and safety in juvenile idiopathic arthritis: a 24-month retrospective study at a single center

  2024influential citation
• Management of Psoriasis Patients with Serious Infectious Diseases

  2024influential citation
• Tuberculosis reactivation following apremilast therapy for psoriasis: Time to consider routine TB screening?

  2024cites this paper
• Flow cytometry-based method using diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease.

  2024cites this paper
• Treatment Related Adverse Events and Monitoring of Patients Receiving Biologic or Small Molecule Therapy for Inflammatory Bowel Disease

  2024cites this paper
• (Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review.

  2024cites this paper
• Emerging Therapeutic Options for Refractory Pulmonary Sarcoidosis: The Evidence and Proposed Mechanisms of Action

  2023cites this paper
• Mucosal and systemic immune responses after a single intranasal dose of nanoparticle and spore-based subunit vaccines in mice with pre-existing lung mycobacterial immunity

  2023cites this paper
• Miliary Tuberculosis during R-MPV Therapy in an Elderly Patient with Primary Central Nerve System Lymphoma: A Case Report

  2023cites this paper
• Complex Case of Tuberculosis Lymphadenitis with Concurrent Takayasu Arteritis in a 14-Year-Old Girl from Ethiopia

  2023cites this paper
• Chapitre 10: Le traitement de la tuberculose active chez les populations particulières

  2023cites this paper
• Serious infections and tuberculosis in psoriasis patients receiving systemic therapy in Korea: a nationwide population-based cohort study

  2023cites this paper
• New‐onset extrapulmonary tuberculosis in negative latent tuberculosis infection screening patients with Crohn's disease under anti‐TNF therapy in a tuberculosis‐endemic region: A case series

  2023cites this paper
• Pediyatrik Romatoloji Hastalarında Tüberküloz Enfeksiyonu Tanısında TNF-Alfa Blokörü Kullanımı Öncesi İnterferon-Gama Salınım Testlerinin Tanısal Değeri

  2023influential citation
• Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.

  2023cites this paper
• Diagnostic Value of Interferon-Gamma Release Assay in the Diagnosis of Tuberculosis Infection Before the Use of TNF-Alpha Blocker in Pediatric Rheumatology Patients

  2023influential citation
• Adalimumab-Induced Isolated Peritoneal Tuberculosis

  2023cites this paper
• Diagnosis of Tuberculosis in a Case of Chronic Urticaria following Omalizumab Therapy

  2023cites this paper
• Immune dysregulation and pathogenic pathways mediated by common infections in rheumatoid arthritis

  2023cites this paper
• Evaluation of tuberculosis in children using biological agent therapy

  2023cites this paper
• Effectiveness of screening in patients with rheumatic disease on biological therapy and risk of active tuberculosis

  2023cites this paper
• Haemophagocytic lymphohistiocytosis secondary to disseminated tuberculosis in a young adult with Crohn's disease

  2023cites this paper
• Musculoskeletal tuberculosis with spinal involvement: An important differential for chronic recurrent multifocal osteomyelitis.

  2022cites this paper
• Active and Latent Tuberculosis in Children Treated with Anti-TNF-α: A Retrospective Multicenter Study

  2022cites this paper
• Position statement of the Spanish Society of Pediatric Rheumatology on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies: Part 1 (screening)

  2022cites this paper
• Targeting ectromelia virus and TNF/NF-κB or STAT3 signaling for effective treatment of viral pneumonia

  2022cites this paper
• Interleukin-27 in Tuberculosis: A Sheep in Wolf’s Clothing?

  2022cites this paper
• Biomarkers to identify Mycobacterium tuberculosis infection among borderline QuantiFERON results

  2022cites this paper
• Differential recognition and cytokine induction by the peptidorhamnomannan from Sporothrix brasiliensis and S. schenckii

  2022cites this paper
• Pyoderma gangrenosum with pulmonary involvement: a pulmonary special report and literature review

  2022cites this paper
• TNFR2 depletion reduces psoriatic inflammation in mice via downregulating specific dendritic cell populations in lymph nodes and inhibiting IL-23/IL-17 pathways.

  2022cites this paper
• Chapter 10: Treatment of active tuberculosis in special populations

  2022cites this paper
• Strengthening Tuberculosis Services for Children and Adolescents in Low Endemic Settings

  2022cites this paper
• FGF15 Protects Septic Mice by Inhibiting Inflammation and Modulating Treg Responses

  2022cites this paper
• [Tuberculosis in adulthood - The Sk2-Guideline of the German Central Committee against Tuberculosis (DZK) and the German Respiratory Society (DGP) for the diagnosis and treatment of adult tuberculosis patients].

  2022cites this paper
• Dual latent tuberculosis screening with tuberculin skin tests and QuantiFERON-TB assays before TNF-α inhibitor initiation in children in Spain

  2022cites this paper
• Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression—risks, screening, diagnosis and management

  2022cites this paper
• Tuberkulose bei Kindern und Jugendlichen unter Therapie mit TNF-α-Inhibitoren

  2022cites this paper
• Management of Psoriatic Erythroderma (PsE) with Ayurvedic herbomineral preparations: A case report

  2022cites this paper
• Rates of latent and active tuberculosis in BGC vaccinated, immunosuppressed Crohn's disease patients form Bulgaria before and during anti-tumor necrosis factor therapy.

  2022cites this paper
• Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease

  2021cites this paper
• TNF-α Inhibitors for the Management of Intractable Corneal Melt: Report of Three Cases and Review of the Literature

  2021cites this paper
• [Guideline for the Treatment and Prevention of Infections Associated with Immunosuppressive Therapy for Autoimmune Diseases].

  2021cites this paper
• Safety of latent tuberculosis infection treatment in older patients with immune-mediated inflammatory diseases

  2021cites this paper
• Tuberculosis infection under anti-TNF alpha treatment.

  2021cites this paper
• Prevalence and factors associated with diabetes mellitus among tuberculosis patients in South India—a cross-sectional analytical study

  2021cites this paper
• Rare manifestation of a large stenosing gastrointestinal tumor caused by Mycobacterium tuberculosis in a previously healthy man from Austria

  2021cites this paper
• The risk of tuberculosis infection in 410 Saudipatients receiving adalimumab therapy

  2021cites this paper
• Patterns of T and B cell responses to Mycobacterium tuberculosis membrane-associated antigens and their relationship with disease activity in rheumatoid arthritis patients with latent tuberculosis infection

  2021cites this paper
• Screening of Latent Tuberculous Infection (LTBI) before Starting Anti-Tumor Necrosis Factor Therapy in Patients with Psoriasis: A Primer for Clinical Dermatologist

  2021cites this paper
• Lung Function sequelae in COVID-19 Patients 3 Months After Hospital Discharge

  2021cites this paper
• Tuberculosis, Alcohol, Smoking, Diabetes, Immune Deficiencies and Immunomodulating Drugs

  2021cites this paper
• Tumor Necrosis Factor Inhibitors Exacerbate Whipple’s Disease by Reprogramming Macrophage and Inducing Apoptosis

  2021cites this paper
• Utility of interferon gamma/tumor necrosis factor alpha FluoroSpot assay in differentiation between active tuberculosis and latent tuberculosis infection: a pilot study

  2021cites this paper
• Biologic therapies for the treatment of psoriatic arthritis

  2021cites this paper
• Lung Function sequelae in COVID-19 Patients 3 Months After Hospital Discharge

  2021cites this paper
• Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals

  2021cites this paper
• Targeting tumour necrosis factor to ameliorate viral pneumonia

  2021cites this paper
• Evaluating safety and compatibility of anti-tumor necrosis factor therapy in patients with connective tissue disorders

  2021cites this paper
• Influence of cytokine release syndrome in severe COVID-19 patients treated with tocilizumab over the Quantiferon TB Gold Plus results

  2021cites this paper
• Screening for latent tuberculosis before starting TNF-alpha inhibitors in a population with high BCG vaccination rates

  2021cites this paper
• Recombinant ArgF PLGA nanoparticles enhances BCG induced immune responses against Mycobacterium bovis infection.

  2021cites this paper
• Potential disease trigger as a therapeutic option: infliximab for paradoxical reaction in tuberculosis of the central nervous system

  2021cites this paper
• Treatment of rheumatoid arthritis patients – a challenge

  2020cites this paper
• Atypische bakterielle Infektionen: Mykobakteriosen

  2020cites this paper
• The Role of gp130 Cytokines in Tuberculosis

  2020cites this paper